Compare BGT & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGT | PRQR |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.3M | 250.7M |
| IPO Year | N/A | 2014 |
| Metric | BGT | PRQR |
|---|---|---|
| Price | $11.35 | $2.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.14 |
| AVG Volume (30 Days) | 107.2K | ★ 591.4K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 10.77% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,859,556.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.89 | $1.07 |
| 52 Week High | $13.42 | $3.10 |
| Indicator | BGT | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 50.09 | 44.60 |
| Support Level | $11.20 | $2.15 |
| Resistance Level | $11.34 | $2.49 |
| Average True Range (ATR) | 0.11 | 0.18 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 93.97 | 33.91 |
Blackrock Floating Rate Income Trust is a closed-end management investment company. Its investment objective is to provide a high level of current income. The company's secondary investment objective is to seek the preservation of capital. The Trust seeks to achieve its investment objectives by investing mainly, under normal conditions, at least 80% of its assets in floating and variable rate instruments of U.S. and non-U.S. issuers, including a substantial portion of its assets in floating and variable rate securities including senior secured floating rate loans made to corporate and other business entities.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.